The innovative drug sector surged with multiple stocks hitting daily price limits, driving the three major indexes higher at opening. Solid-state battery concepts and rare earth materials led gains, while traditional sectors like banking, gold, and nonferrous metals lagged behind. The divergent performance highlights investors’ continued preference for high-growth technology and biotech plays over cyclical industries.
Yue Hongyuan A (000573) surged 10% to 4.08 yuan despite announcing the termination of its planned acquisition of Bochuang Intelligent Equipment. The real estate-focused firm had sought to diversify into intelligent injection molding equipment – a strategic emerging industry – but will now maintain its core property and recycled lead operations. The stock’s limit-up suggests market approval for disciplined capital allocation.
Today’s trading patterns underscore how policy-driven emerging industries are outperforming traditional sectors. The innovative drug rally reflects sustained confidence in China’s biotech pipeline, while abandoned M&A deals like Yue Hongyuan’s demonstrate investors rewarding prudent corporate strategy over indiscriminate diversification in uncertain markets.
Related topics：
